| Product Name | CRP ELISA kit (Rat) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of High Sensitive C Reactive Protein (CRP). No significant cross-reactivity or interference between High Sensitive C Reactive Protein (CRP) and analogues was observed. |
| Synonyms | C-RP; PTX1; Pentraxin-Related; Pentraxin 1 |
| Method | Sandwich |
| Detection Range | 15.6-1,000pg/mL |
| Sensitivity | 7.4pg/mL |
| Target | CRP |
| Specificity | This assay has high sensitivity and excellent specificity for detection of High Sensitive C Reactive Protein (CRP). No significant cross-reactivity or interference between High Sensitive C Reactive Protein (CRP) and analogues was observed. |
| Reactivity | Rat |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P48199 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Perirenal fat associated with microalbuminuria in obese rats;As If Biomarker Discovery Isn't Hard Enough: The Consequences of Poorly Characterized Reagents; Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta;Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway;Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor–nitric oxide axis in obese rats;Protective Effects of Statin and Angiotensin Receptor Blocker in a Rat Model of Doxorubicin-and Trastuzumab-Induced Cardiomyopathy;Perfluorooctane sulfonate exerts inflammatory bowel disease-like intestinal injury in rats; |
| Supplier | Cloud Clone |
PROTOCOLS:
HEA821Ra All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
